Seek Returns logo

AMGN vs. ASND: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at AMGN and ASND, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

AMGN dominates in value with a market cap of 145.90 billion USD, eclipsing ASND’s 9.55 billion USD by roughly 15.29×.

With betas of 0.50 for AMGN and 0.40 for ASND, both show similar volatility profiles relative to the overall market.

ASND is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike AMGN, which is purely domestic.

SymbolAMGNASND
Company NameAmgen Inc.Ascendis Pharma A/S
CountryUSDK
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralBiotechnology
CEOMr. Robert A. BradwayMr. Jan Moller Mikkelsen
Price271.34 USD158.1 USD
Market Cap145.90 billion USD9.55 billion USD
Beta0.500.40
ExchangeNASDAQNASDAQ
IPO DateJune 17, 1983January 28, 2015
ADRNoYes

Performance Comparison

This chart compares the performance of AMGN and ASND over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of AMGN and ASND based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • ASND shows a negative P/E of -24.59, highlighting a year of losses, whereas AMGN at 24.60 trades on solid profitability.
  • ASND shows a negative forward PEG of -2.23, signaling expected earnings contraction, while AMGN at 7.08 maintains analysts’ projections for stable or improved profits.
  • ASND carries a sub-zero price-to-book ratio of -44.27, indicating negative equity. In contrast, AMGN (P/B 23.52) has positive book value.
  • ASND reports a negative Price-to-Free Cash Flow ratio of -27.48, showing a cash flow shortfall that could threaten its operational sustainability, while AMGN at 13.37 maintains positive cash flow.
SymbolAMGNASND
Price-to-Earnings Ratio (P/E, TTM)24.60-24.59
Forward PEG Ratio (TTM)7.08-2.23
Price-to-Sales Ratio (P/S, TTM)4.2822.92
Price-to-Book Ratio (P/B, TTM)23.52-44.27
Price-to-Free Cash Flow Ratio (P/FCF, TTM)13.37-27.48
EV-to-EBITDA (TTM)15.71-35.80
EV-to-Sales (TTM)5.7023.82
EV-to-Free Cash Flow (TTM)17.82-28.55

Dividend Comparison

AMGN delivers a 3.41% dividend yield, blending income with growth, whereas ASND appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.

SymbolAMGNASND
Dividend Yield (TTM)3.41%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of AMGN and ASND, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • ASND posts a quick ratio of 0.71, indicating limited coverage of short-term debts from its most liquid assets—while AMGN at 0.88 enjoys stronger liquidity resilience.
  • AMGN carries high leverage (debt-to-equity ratio 9.24), whereas ASND has negative equity (-4.46), each presenting distinct capital-structure concerns.
  • AMGN meets its interest obligations (ratio 3.19). In stark contrast, ASND’s negative ratio (-3.72) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
SymbolAMGNASND
Current Ratio (TTM)1.171.04
Quick Ratio (TTM)0.880.71
Debt-to-Equity Ratio (TTM)9.24-4.46
Debt-to-Assets Ratio (TTM)0.640.80
Interest Coverage Ratio (TTM)3.19-3.72